The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid； b) at least one phospholipid； c) at least one biocompatible, organic solvent； d) an alkyl ammonium EDTA salt； and e) at least one somatostatin receptor agonist； wherein the pre-formulation has a water content in the range of 0 to 1.0 wt%. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.本發明係關於預配方，其包含：a)至少一二醯脂類；b)至少一磷脂類；c)至少一生物相容性、有機溶劑；d)一烷基銨EDTA鹽類；以及e)至少一生長激素抑制素受體促效劑；其中該預配方具有介於0至1.0wt%範圍之水分含量。本發明更進一步係關於包括投予前述預配方之治療方法、包含該配方之預填投藥裝置及套組、烷基銨EDTA鹽類在降低脂質成分以及/或任何包含於該預配方內活性物質之分解之用途。
